Catalyst Pharmaceuticals Inc
CPRX21.420USD
+0.300+1.42%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.61BCap. mercado
13.24P/E TTM
Más Datos de Catalyst Pharmaceuticals Inc Compañía
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Información de la empresa
Símbolo de cotizaciónCPRX
Nombre de la empresaCatalyst Pharmaceuticals Inc
Fecha de salida a bolsaNov 08, 2006
Director ejecutivoMr. Richard J. (Rich) Daly
Número de empleados181
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 08
Dirección355 Alhambra Circle
CiudadCORAL GABLES
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33134
Teléfono13055292522
Sitio Webhttps://catalystpharma.com/
Símbolo de cotizaciónCPRX
Fecha de salida a bolsaNov 08, 2006
Director ejecutivoMr. Richard J. (Rich) Daly
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.28M
-4.46%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
949.66K
--
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
495.08K
--
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
355.62K
--
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
199.76K
-25.95%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
188.56K
--
Dr. Gary Ingenito, M.D., Ph.D.
Dr. Gary Ingenito, M.D., Ph.D.
Chief Medical Officer and Regulatory Officer
Chief Medical Officer and Regulatory Officer
68.87K
--
Dr. Preethi Sundaram, Ph.D.
Dr. Preethi Sundaram, Ph.D.
Chief Strategy Officer
Chief Strategy Officer
41.08K
-8.72%
Ms. Molly Harper
Ms. Molly Harper
Lead Independent Director
Lead Independent Director
6.75K
--
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
1.41K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Patrick James Mcenany
Mr. Patrick James Mcenany
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.28M
-4.46%
Dr. Steven R. Miller, Ph.D.
Dr. Steven R. Miller, Ph.D.
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
Executive Vice President, Chief Operating Officer, and Chief Scientific Officer
949.66K
--
Mr. Donald A. Denkhaus
Mr. Donald A. Denkhaus
Independent Director
Independent Director
495.08K
--
Dr. David S. Tierney, M.D.
Dr. David S. Tierney, M.D.
Independent Director
Independent Director
355.62K
--
Mr. Richard J. (Rich) Daly
Mr. Richard J. (Rich) Daly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
199.76K
-25.95%
Mr. Brian D. Elsbernd, J.D.
Mr. Brian D. Elsbernd, J.D.
Chief Compliance Officer, Chief Legal Officer
Chief Compliance Officer, Chief Legal Officer
188.56K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.46%
The Vanguard Group, Inc.
6.95%
State Street Global Advisors (US)
4.53%
McEnany (Patrick James)
3.51%
Deerfield Management Company, L.P.
2.81%
Other
68.75%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.46%
The Vanguard Group, Inc.
6.95%
State Street Global Advisors (US)
4.53%
McEnany (Patrick James)
3.51%
Deerfield Management Company, L.P.
2.81%
Other
68.75%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
43.94%
Investment Advisor/Hedge Fund
24.40%
Hedge Fund
8.56%
Individual Investor
6.05%
Research Firm
4.41%
Pension Fund
1.27%
Bank and Trust
0.44%
Family Office
0.17%
Sovereign Wealth Fund
0.10%
Other
10.67%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
675
109.00M
89.36%
-4.26M
2025Q1
693
109.47M
89.76%
-3.79M
2024Q4
658
108.09M
89.06%
-2.57M
2024Q3
628
104.82M
88.36%
-8.18M
2024Q2
597
106.41M
90.13%
-15.99M
2024Q1
590
105.68M
89.66%
-4.79M
2023Q4
569
93.52M
87.71%
-15.08M
2023Q3
548
90.12M
84.55%
-19.61M
2023Q2
542
91.66M
86.51%
-22.59M
2023Q1
518
97.83M
92.70%
-11.38M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
16.42M
13.46%
-409.06K
-2.43%
Mar 31, 2025
The Vanguard Group, Inc.
8.47M
6.95%
+64.49K
+0.77%
Mar 31, 2025
State Street Global Advisors (US)
5.53M
4.53%
-266.12K
-4.59%
Mar 31, 2025
McEnany (Patrick James)
4.28M
3.51%
-200.00K
-4.46%
Jun 09, 2025
Deerfield Management Company, L.P.
3.42M
2.81%
+289.14K
+9.23%
Mar 31, 2025
Renaissance Technologies LLC
2.96M
2.42%
+250.20K
+9.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.77M
2.27%
+100.08K
+3.75%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.19M
1.79%
-825.61K
-27.40%
Mar 31, 2025
Fundsmith LLP
2.15M
1.76%
+2.15M
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
1.77M
1.45%
+371.01K
+26.53%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
3.69%
Tema Neuroscience and Mental Health ETF
2.92%
Invesco Biotechnology & Genome ETF
2.32%
Invesco S&P SmallCap 600 GARP ETF
2.01%
Invesco S&P SmallCap Health Care ETF
1.78%
AAM Sawgrass US Small Cap Quality Growth ETF
1.65%
Invesco Dorsey Wright Healthcare Momentum ETF
1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.56%
Janus Henderson Small Cap Growth Alpha ETF
1.52%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.44%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción3.69%
Tema Neuroscience and Mental Health ETF
Proporción2.92%
Invesco Biotechnology & Genome ETF
Proporción2.32%
Invesco S&P SmallCap 600 GARP ETF
Proporción2.01%
Invesco S&P SmallCap Health Care ETF
Proporción1.78%
AAM Sawgrass US Small Cap Quality Growth ETF
Proporción1.65%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporción1.56%
Janus Henderson Small Cap Growth Alpha ETF
Proporción1.52%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción1.44%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
